These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 24989901

  • 1. Incidence of deferasirox-associated renal tubular dysfunction in children and young adults with beta-thalassaemia.
    Dee CM, Cheuk DK, Ha SY, Chiang AK, Chan GC.
    Br J Haematol; 2014 Nov; 167(3):434-6. PubMed ID: 24989901
    [No Abstract] [Full Text] [Related]

  • 2. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.
    Economou M, Printza N, Teli A, Tzimouli V, Tsatra I, Papachristou F, Athanassiou-Metaxa M.
    Acta Haematol; 2010 Nov; 123(3):148-52. PubMed ID: 20185899
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Acquired proximal renal tubular dysfunction in β-thalassemia patients treated with deferasirox.
    Yacobovich J, Stark P, Barzilai-Birenbaum S, Krause I, Pazgal I, Yaniv I, Tamary H.
    J Pediatr Hematol Oncol; 2010 Oct; 32(7):564-7. PubMed ID: 20733517
    [Abstract] [Full Text] [Related]

  • 5. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
    Balocco M, Carrara P, Pinto V, Forni GL.
    Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
    [No Abstract] [Full Text] [Related]

  • 6. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
    Tanphaichitr A, Kusuwan T, Limviriyakul S, Atipas S, Pooliam J, Sangpraypan T, Tanphaichitr VS, Viprakasit V.
    Hemoglobin; 2014 Jun; 38(5):345-50. PubMed ID: 25051423
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of deferasirox in β-thalassemia major patients in Iran: a prospective study from a single referral center in Iran.
    Alavi S, Ebadi M, Ghazizadeh F, Arzanian MT, Shamsian B, Abdollah Gorji F.
    Pediatr Hematol Oncol; 2014 Feb; 31(1):76-86. PubMed ID: 24383712
    [Abstract] [Full Text] [Related]

  • 10. Reversible Fanconi syndrome in a pediatric patient on deferasirox.
    Rheault MN, Bechtel H, Neglia JP, Kashtan CE.
    Pediatr Blood Cancer; 2011 Apr; 56(4):674-6. PubMed ID: 21298760
    [Abstract] [Full Text] [Related]

  • 11. Deferasirox effect on renal haemodynamic parameters in patients with transfusion-dependent β thalassaemia.
    Piga A, Fracchia S, Lai ME, Cappellini MD, Hirschberg R, Habr D, Wegener A, Bouillaud E, Forni GL.
    Br J Haematol; 2015 Mar; 168(6):882-90. PubMed ID: 25402221
    [Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of deferasirox in multitransfused Indian children with β-thalassaemia major.
    Chandra J, Chaudhary H, Pemde H, Singh V, Dutta AK.
    Ann Trop Paediatr; 2011 Mar; 31(1):47-51. PubMed ID: 21262109
    [Abstract] [Full Text] [Related]

  • 13. Iron chelation therapy of transfusion-dependent β-thalassemia during pregnancy in the era of novel drugs: is deferasirox toxic?
    Diamantidis MD, Neokleous N, Agapidou A, Vetsiou E, Manafas A, Fotiou P, Vlachaki E.
    Int J Hematol; 2016 May; 103(5):537-44. PubMed ID: 26861970
    [Abstract] [Full Text] [Related]

  • 14. Compliance and satisfaction with deferasirox (Exjade®) compared with deferoxamine in patients with transfusion-dependent beta-thalassemia.
    Haghpanah S, Zarei T, Zahedi Z, Karimi M.
    Hematology; 2014 Jun; 19(4):187-91. PubMed ID: 24074344
    [Abstract] [Full Text] [Related]

  • 15. A prospective study of tubular dysfunction in pediatric patients with Beta thalassemia major receiving deferasirox.
    Naderi M, Sadeghi-Bojd S, Valeshabad AK, Jahantigh A, Alizadeh S, Dorgalaleh A, Tabibian S, Bamedi T.
    Pediatr Hematol Oncol; 2013 Nov; 30(8):748-54. PubMed ID: 24134694
    [Abstract] [Full Text] [Related]

  • 16. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
    Saliba AN, El Rassi F, Taher AT.
    Expert Rev Hematol; 2016 Nov; 9(2):151-68. PubMed ID: 26613264
    [Abstract] [Full Text] [Related]

  • 17. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up.
    Cappellini MD, Bejaoui M, Agaoglu L, Canatan D, Capra M, Cohen A, Drelichman G, Economou M, Fattoum S, Kattamis A, Kilinc Y, Perrotta S, Piga A, Porter JB, Griffel L, Dong V, Clark J, Aydinok Y.
    Blood; 2011 Jul 28; 118(4):884-93. PubMed ID: 21628399
    [Abstract] [Full Text] [Related]

  • 18. Transparency and access to full information for the fatal or serious toxicity risks, low efficacy and high price of deferasirox, could increase the prospect of improved iron chelation therapy worldwide.
    Kontoghiorghes GJ.
    Hemoglobin; 2008 Jul 28; 32(6):608-15. PubMed ID: 19065341
    [No Abstract] [Full Text] [Related]

  • 19. Deferasirox for cardiac siderosis in β-thalassaemia major: a multicentre, open label, prospective study.
    Piga A, Longo F, Origa R, Roggero S, Pinna F, Zappu A, Castiglioni C, Cappellini MD.
    Br J Haematol; 2014 Nov 28; 167(3):423-6. PubMed ID: 24976388
    [No Abstract] [Full Text] [Related]

  • 20. Fanconi syndrome in a patient with β-thalassemia major after using deferasirox for 27 months.
    Wei HY, Yang CP, Cheng CH, Lo FS.
    Transfusion; 2011 May 28; 51(5):949-54. PubMed ID: 21077910
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.